Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events.

If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

00420 224 910 672

(from 09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

To contact us about any other issue please call:

+420 22 491 0000or our regional offices.

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

00420 224 910 672

(09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

Global pharmaceutical regulatory affairs specialist ELC Group establishes new office in Singapore

ELC Group boosts support for customers across South East Asian region with new regional office

Cambridge, UK, November 7th 2012 – ELC GROUP, one of the fastest growing providers of regulatory affairs consulting services, today announces the opening of a new operational office in Singapore, its first in the region. The new office will bolster ELC Group’s support for EU customers in North East Asia, South East Asia, Australia and New Zealand, and will enhance the delivery of localised services to Asian clients operating both within the region and in the EU, US and Latin America.

The Singapore office opening follows a strong year for growth for ELC Group, which in 2012 has already announced office openings and expansions in Mumbai, Ahmedabad and Cambridge. The newly-opened Singapore office will be staffed by an experienced team of regulatory affairs professionals, including pharmacists, clinical experts, pharmaceutical Chemistry, Manufacturing and Control (CMC) experts, chemists, medical device experts and regulatory strategists. The regional operation is being jointly headed by Mr. Choi Chai Wei, Senior Manager Technical Sales, who will provide ELC GROUP’s executive and technical teams with strategic counsel to further advance the company’s product vision in the Asia-Pacific region, and Mr. Akhil Jain, Vice President, Business Development for ELC Group. Before ELC GROUP, Mr. Choi Chai Wei was a senior Regulatory & QA Manager at DHL Healthcare Hub, and prior to that, he worked for Schwabe Pharma as Director of Product Management. Mr. Choi Chai Wei earned his MBA at the University of Bradford, UK in 1986.

The management team will lead the commercial development and delivery of ELC Group’s comprehensive portfolio of services, including local representation, partner finding, market intelligence, clinical trial management and support, and full-service regulatory affairs for pharmaceutical drugs, medical devices and food supplements.

Commenting on the office opening, Marco Rubinstein, CEO of ELC Group said: “Singapore is a strategically idea base to manage our operations in South East Asia, and offers us superb access to the highly skilled, multilingual specialists that we need to deliver first-class regulatory services to our customers operating in this region.” He added: “We see this new office as an important launch pad for ELC Group’s further expansion and market dominance in the Australasian and Pacific regions, which includes our plans to set up a dedicated office in China in the very near future.”